Q: With the deal with Sarepta including a few SCA programs in Huntington's with the Sub Q delivery, how are you thinking about the future of Arrowhead's CNS franchise from here? A: Christopher Anzalone, President and CEO: The sub Q CNS platform is exciting, and we have other programs like MAPT and ALUCAN that remain wholly owned. These are potentially partnerable, and we see potential CNS targets in the cardiometabolic space. We expect updates in 2025.

Q: What was your reaction to Lilly discontinuing their siRNA for APOC3? A: Bruce Given, Chief Operating Officer & Head of R&D: It's hard to assess from a distance, but pos' is a strong drug and may have set a high bar. However, I can't determine why Lilly made that decision.

Q: How are you thinking about paying down the debt announced on the last earnings call? A: Christopher Anzalone, President and CEO: We will pay down the debt through the Sarepta deal and other deals as cash comes in. There are formulas for that, and we expect it to contribute to paying down the debt over time.

Q: How important are the obesity programs, ARO-INHBE and ARO-ALC7, strategically to the company? A: Christopher Anzalone, President and CEO: These are important targets, genetically validated, and we will be the first in the clinic with them. We like our positioning and the genetic data, making them strategically significant.

Q: Given the large partnership with Sarepta, what are your thoughts on additional partnerships going forward? A: Christopher Anzalone, President and CEO: We are still on the lookout for smaller collaborations and license agreements. The Sarepta deal gives us breathing room, but we expect more deals over time, leveraging our discovery capacity and non-core assets.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.